Efficient PD-L1 imaging of murine glioblastoma with FUS-aided immunoPET by leveraging FcRn-antibody interaction
Theranostics · 2023
DOI: 10.7150/thno.87168 ↗Kurz gefasst
Fachartikel in der Zeitschrift Theranostics, 2023. Verfasst von Céline Chevaleyre und 11 weiteren Autor:innen. Beteiligte Einrichtung: Paris-Saclay University, CEA, CNRS, Inserm, BioMaps, Service Hospitalier Frédéric Joliot, Orsay France. Hauptthemen laut MEDLINE: B7-H1 Antigen, Glioblastoma. Die Arbeit wurde bisher 26-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Rationale
The passage of antibodies through the blood-brain barrier (BBB) and the blood-tumoral barrier (BTB) is determinant not only to increase the immune checkpoint inhibitors efficacy but also to monitor prognostic and predictive biomarkers such as the programmed death ligand 1 (PD-L1) via immunoPET. Although the involvement of neonatal Fc receptor (FcRn) in antibody distribution has been demonstrated, its function at the BBB remains controversial, while it is unknown at the BTB. In this context, we assessed FcRn's role by pharmacokinetic immunoPET imaging combined with focused ultrasounds (FUS) using unmodified and FcRn low-affinity IgGs targeting PD-L1 in a preclinical orthotopic glioblastoma model.
Methods
Transcranial FUS were applied over the whole brain in mice shortly before injecting the anti-PD-L1 IgG 89Zr-DFO-C4 or its FcRn low-affinity mutant 89Zr-DFO-C4Fc-MUT in a syngeneic glioblastoma murine model (GL261-GFP). Brain uptake was measured from PET scans acquired up to 7 days post-injection. Kinetic modeling was performed to compare the brain kinetics of both C4 formats.
Results
FUS efficiently enhanced the delivery of both C4 radioligands in the brain with high reproducibility. 89Zr-DFO-C4Fc-MUT mean concentrations in the brain reached a significant uptake of 3.75±0.41%ID/cc with FUS against 1.92±0.45%ID/cc without, at 1h post-injection. A substantial and similar entry of both C4 radioligands was observed at a rate of 0.163±0.071 mL/h/g of tissue during 10.4±4.6min. The impaired interaction with FcRn of 89Zr-DFO-C4Fc-MUT significantly decreased the efflux constant from the healthy brain tissue to plasma compared with non-mutated IgG. Abolishing FcRn interaction allows determining the target engagement related to the specific binding as soon as 12h post-injection.
Conclusion
Abolishing Fc-FcRn interaction confers improved kinetic properties to 89Zr-DFO-C4Fc-MUT for immunoPET imaging. FUS-aided BBB/BTB disruption enables quantitative imaging of PD-L1 expression by glioblastoma tumors within the brain.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Paris-Saclay University, CEA, CNRS, Inserm, BioMaps, Service Hospitalier Frédéric Joliot, Orsay France.
- Paris-Saclay University, CEA, INRAE, Medicines and Healthcare Technologies Department, SIMoS, Gif-sur-Yvette, France.
- Paris-Saclay University, CEA, CNRS, NeuroSpin/BAOBAB, Centre d'études de Saclay, Bâtiment 145, 91191 Gif sur Yvette, France.
Zitieren
APA
Chevaleyre, C., Novell, A., Tournier, N., Dauba, A., Dubois, S., Kereselidze, D., Selingue, E., Jego, B., Maillère, B., Larrat, B., Nozach, H., & Truillet, C. (2023). Efficient PD-L1 imaging of murine glioblastoma with FUS-aided immunoPET by leveraging FcRn-antibody interaction. Theranostics. https://doi.org/10.7150/thno.87168
Vancouver
Chevaleyre C, Novell A, Tournier N, Dauba A, Dubois S, Kereselidze D, et al. Efficient PD-L1 imaging of murine glioblastoma with FUS-aided immunoPET by leveraging FcRn-antibody interaction. Theranostics. 2023. doi:10.7150/thno.87168
BibTeX
@article{Chevaleyre2023,
author = {Chevaleyre, Céline and Novell, Anthony and Tournier, Nicolas and Dauba, Ambre and Dubois, Steven and Kereselidze, Dimitri and Selingue, Erwan and Jego, Benoit and Maillère, Bernard and Larrat, Benoit and Nozach, Hervé and Truillet, Charles},
title = {Efficient PD-L1 imaging of murine glioblastoma with FUS-aided immunoPET by leveraging FcRn-antibody interaction},
journal = {Theranostics},
year = {2023},
doi = {10.7150/thno.87168}
}
EUVIMED